Janus Henderson Group PLC acquired a new stake in shares of Rubius Therapeutics Inc (NASDAQ:RUBY) during the first quarter, according to its most recent filing with the SEC. The fund acquired 828,458 shares of the company’s stock, valued at approximately $14,995,000.
Several other large investors also recently added to or reduced their stakes in RUBY. BlackRock Inc. bought a new stake in shares of Rubius Therapeutics during the 3rd quarter valued at $38,155,000. Vanguard Group Inc bought a new position in Rubius Therapeutics in the 3rd quarter worth about $23,329,000. Vanguard Group Inc. bought a new position in Rubius Therapeutics in the 3rd quarter worth about $23,329,000. Norges Bank bought a new position in Rubius Therapeutics in the 4th quarter worth about $7,236,000. Finally, Federated Investors Inc. PA bought a new position in Rubius Therapeutics in the 3rd quarter worth about $8,400,000. Institutional investors own 88.93% of the company’s stock.
Separately, Zacks Investment Research upgraded Rubius Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research note on Wednesday, January 16th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Rubius Therapeutics currently has an average rating of “Buy” and a consensus price target of $30.00.
Shares of NASDAQ RUBY opened at $15.80 on Thursday. The stock has a market capitalization of $1.20 billion and a price-to-earnings ratio of -6.96. The company has a debt-to-equity ratio of 0.17, a quick ratio of 20.72 and a current ratio of 20.72. Rubius Therapeutics Inc has a twelve month low of $12.70 and a twelve month high of $33.01.
Rubius Therapeutics (NASDAQ:RUBY) last announced its earnings results on Wednesday, May 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.04). Research analysts forecast that Rubius Therapeutics Inc will post -1.71 EPS for the current fiscal year.
In other Rubius Therapeutics news, insider Christopher L. Carpenter sold 48,000 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $15.84, for a total value of $760,320.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Torben Straight Nissen sold 2,100 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $20.00, for a total value of $42,000.00. The disclosure for this sale can be found here. Insiders sold a total of 70,196 shares of company stock worth $1,186,015 over the last 90 days. Corporate insiders own 58.40% of the company’s stock.
Rubius Therapeutics Profile
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria.
Recommended Story: Backdoor Roth IRA
Want to see what other hedge funds are holding RUBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Rubius Therapeutics Inc (NASDAQ:RUBY).